Societal CDMO, Inc. announced new project expansion agreements with several existing customers. The six new scopes of work across four different current customers highlight Societal's ability to drive revenue growth through the ongoing strengthening and maturation of existing relationships. The recently signed work expansion agreements include: Increasing the batch size for an ongoing design of experiments (DoE) study of an approved chemotherapeutic agent, with incorporation of additional blending and compaction specifications for the tablets.

Execution of surrogate batch manufacturing and testing for an approved chemotherapeutic agents, as well as manufacturing of a development batch for a coating DOE study of the same compound. Analytical method development and validation, along with clinical trial material batch manufacturing of a fixed-dose combination of an approved chemotherape therapeutic agent and a compound that enhances the chemotherapeutic agent's bioavailability and systemic exposure. Broadening of clinical trial services related to a U.S.-based Phase 2 clinical study of a novel melatonergic antidepressant already approved for use in Europe and Australia.